Motapizone

Motapizone (NAT 05-239) is a selective PDE3 inhibitor. Motapizone moderately inhibits cytokine release in lipopolysaccharide (LPS) -induced alveolar macrophages. Motapizone also inhibits human platelet aggregation by increasing intracellular cAMP[1][2].

Product Specifications

CAS Number

[90697-57-7]

Product Name Alternative

NAT 05-239

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/motapizone.html

Purity

95.0

Solubility

DMSO : 2.7 mg/mL (ultrasonic)

Smiles

CC(C1)C(C2=CC(N3C=CN=C3)=CS2)=NNC1=O

Molecular Formula

C12H12N4OS

Molecular Weight

260.32

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Milara J, et al. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 2011 Apr;41 (4) :535-46. |[2]Borbe HO, et al. Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP. Agents Actions Suppl. 1986;20:249-57.